2022
MIF is a common genetic determinant of COVID-19 symptomatic infection and severity
Shin JJ, Fan W, Par-Young J, Piecychna M, Leng L, Israni-Winger K, Qing H, Gu J, Zhao H, Schulz WL, Unlu S, Kuster J, Young G, Liu J, Ko AI, Garcia A, Sauler M, Wisnewski AV, Young L, Orduña A, Wang A, Klementina O, Garcia AB, Hegyi P, Armstrong ME, Mitchell P, Ordiz DB, Garami A, Kang I, Bucala R. MIF is a common genetic determinant of COVID-19 symptomatic infection and severity. QJM 2022, 116: 205-212. PMID: 36222594, PMCID: PMC9620729, DOI: 10.1093/qjmed/hcac234.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorLow-expression MIF alleleCOVID-19 infectionMIF allelesCATT7 alleleHealthy controlsCOVID-19Serum macrophage migration inhibitory factorSymptomatic SARS-CoV-2 infectionHigher serum MIF levelsHigh-expression MIF allelesRetrospective case-control studySARS-CoV-2 infectionFunctional polymorphismsAvailable clinical characteristicsMultinational retrospective studySerum MIF levelsUninfected healthy controlsSymptomatic COVID-19Tertiary medical centerHealthy control subjectsCase-control studyMigration inhibitory factorCoronavirus disease 2019Common functional polymorphisms
2011
Pathogenesis and Disease Mechanisms of Occupational Asthma
Lummus ZL, Wisnewski AV, Bernstein DI. Pathogenesis and Disease Mechanisms of Occupational Asthma. Immunology And Allergy Clinics Of North America 2011, 31: 699-716. PMID: 21978852, PMCID: PMC4683932, DOI: 10.1016/j.iac.2011.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAirway RemodelingAllergensAsthma, OccupationalBronchial HyperreactivityGenetic Predisposition to DiseaseHumansImmunity, InnateImmunoglobulin EIrritantsOccupational ExposureOxidative StressRisk FactorsConceptsOccupational asthmaWork-related lung diseaseMultifactorial pathogenetic mechanismsGenetic susceptibility factorsNonimmunologic mechanismsLung diseaseClinical managementInflammatory processPathogenetic mechanismsSusceptibility factorsDisease mechanismsCommon formAsthmaDiseasePatientsPathogenesis
2003
Recent developments in diisocyanate asthma
Liu Q, Wisnewski AV. Recent developments in diisocyanate asthma. Annals Of Allergy Asthma & Immunology 2003, 90: 35-41. PMID: 12772950, DOI: 10.1016/s1081-1206(10)61647-x.Peer-Reviewed Original ResearchMeSH KeywordsAsthmaCyanatesEpithelial CellsFollow-Up StudiesGenetic Predisposition to DiseaseHumansIsocyanatesLungOccupational DiseasesOccupational ExposureSkinToluene 2,4-DiisocyanateConceptsDiisocyanate asthmaPotential long-term adverse effectsMajor histocompatibility complex class II allelesLong-term adverse effectsGlutathione S-transferase polymorphismsImmune-dependent mechanismsAntigen-independent mechanismsLong-term followGenetic factorsHuman immune responseClass II allelesEffective diagnostic testAllergic asthmaAsthma patientsAtopic asthmaDiisocyanate exposureSymptomatic patientsImmune basisSensitized patientsAsthma pathogenesisPrognostic valueImmunologic differencesAirway epitheliumImmune responseAsthma
2001
Recent developments in diisocyanate asthma
Wisnewski A, Redlich C. Recent developments in diisocyanate asthma. Current Opinion In Allergy And Clinical Immunology 2001, 1: 169. PMID: 11964686, DOI: 10.1097/00130832-200104000-00009.Peer-Reviewed Original ResearchMeSH KeywordsAsthmaCyanatesGenes, MHC Class IIGenetic Predisposition to DiseaseHumansImmunoglobulin EImmunoglobulin GIsocyanatesSkinT-Lymphocytes, Helper-InducerToluene 2,4-Diisocyanate